Oncotide: SETting up phosphatases

Oncotide SET antagonists enhance phosphatase activity, disrupt cancer signaling

Oncotide Pharmaceuticals Inc. believes it has found a way to deactivate the phosphorylation that is a driver of oncogenic signaling, an approach that could provide an alternative or add-on to kinase inhibitors for blocking growth of tumor cells.

Rather than inhibiting kinases to restore normal phosphorylation and reduce the signaling of up-regulated oncogenic pathways, Oncotide is developing SET inhibitors to promote dephosphorylation of the oncogenic signaling molecules.

President and CSO Dale Christensen said disruptions in both kinase and

Read the full 769 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE